Clarity Pharmaceuticals (ASX: $CU6) SECURE trial update

Clarity Pharmaceuticals (ASX: $CU6) has dosed the first participant in the final cohort, cohort 4, of the SECURE trial. The trial investigates the use of 67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer patients, with the first multi-dose cohort participant receiving 12GBq of the treatment.

Executive Commentary from Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals

Treating the first participant in cohort 4 just a week after announcing the safety review from cohort 3 and opening cohort 4 is remarkable. With all available slots now allocated in the first part of cohort 4, we look forward to completing this final cohort in the dose escalation stage of the trial and moving to dose expansion, where we plan to enroll 14 patients. This high pace of recruitment into the SECURE trial reflects the high unmet need in the prostate cancer therapy space as well as clinicians' excitement about our SAR-bisPSMA product.

Summary of SECURE trial progress and outlook

Clarity Pharmaceuticals (ASX: $CU6) has successfully treated the first participant in the final cohort of the SECURE trial, marking progress in the dose escalation phase. The preliminary data shows a favorable safety profile of 67Cu-SAR-bisPSMA, with no dose limiting toxicities reported in any trial participants to date. The company aims to move into the dose expansion phase with 14 participants pending safety evaluation. The high pace of recruitment reflects the unmet need in prostate cancer therapy, and the company's strong belief in the efficacy and safety profile of their product. The data continues to reinforce their commitment to improving treatment outcomes for people with cancer.